Lifshitz & Miller LLP Announces Investigation of CBBC Bancorp, Clifton Bancorp Inc., Dynegy, Inc., GenMark Diagnostics, Inc., Impax Laboratories, Inc., RPM International Inc. and XBiotech Inc.

NEW YORK, Nov. 16, 2017 /PRNewswire/ --

CBBC Bancorp (CBBC)

Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the board in connection with the proposed sale of CBBC to Suncrest Bank in which CBBC shareholders may elect to receive either $23.75 cash or 2.262 Suncrest shares.

If you are a CBBC investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Clifton Bancorp Inc. (CSBK)

Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the board in connection with the proposed sale of CSBK to Kearny Financial Corp. in which CSBK shareholders will receive 1.191 Kearny shares for each CSBK share.

If you are a CSBK investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Dynegy, Inc. (DYN)

Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the board in connection with the proposed sale of DYN to Vistra Energy Corporation in which DYN shareholders will receive 0.652 Vistra shares for each DYN share.

If you are a DYN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

GenMark Diagnostics, Inc. (GNMK)

Lifshitz & Miller announces an investigation on behalf of GNMK investors after GNMK disclosed that revenue recognition for expected placements for GNMK's ePlex product was slowed by a longer-than-expected customer evaluation and validation process.

If you are a GNMK investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Impax Laboratories, Inc. (IPXL)

Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the board in connection with the proposed all-stock-merger of IPXL with Amneal Pharmaceuticals in which IPXL shareholders will own 25% of the combined company.

If you are an IPXL investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

RPM International Inc. (RPM)

Lifshitz & Miller announces an investigation on behalf of RPM investors concerning whether RPM failed to disclose a material loss contingency or record an accrual for a government investigation when required to do so.

If you are an RPM investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

XBiotech Inc. (XBIT)

Lifshitz & Miller announces an investigation on behalf of XBIT investors concerning whether XBIT issued false and misleading statements about its European Phase III trial of Xilonix for the treatment of colorectal cancer.

If you are an XBIT investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

ATTORNEY ADVERTISING. © 2017 Lifshitz & Miller LLP.  The law firm responsible for this advertisement is Lifshitz & Miller LLP, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516)493-9780.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:
Joshua M. Lifshitz, Esq.
Lifshitz & Miller LLP
Phone:  516-493-9780
Facsimile: 516-280-7376
Email: [email protected]

SOURCE Lifshitz & Miller